References
- The World Bank. Feature story. The global economic outlook during the COVID-19 pandemic: a changed world. 2020 Jun 8. https://www.worldbank.org/en/news/feature/2020/06/08/the-global-economic-outlook-during-the-covid-19-pandemic-a-changed-world.
- Drury G, Jolliffec S, Mukhopadhyay TK. Process mapping of vaccines: understanding the limitations in current response to emerging epidemic threats. Vaccine. 2019;37(17):2415–21. doi:10.1016/j.vaccine.2019.01.050.
- IABS WEBINAR, Dr Melanie Saville. https://www.iabs.org/documents/conferences/2020/sars-cov-2-webinar/1376-melanie-saville-2705-vaccine-development-for-covdi19-ms-cepi/file.
- Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969–73. doi:10.1056/NEJMp2005630.
- Rele S. Emerging outbreaks and epidemic threats: the practicality and limitations in the development and manufacturing of treatments for Coronavirus (COVID-19). Polymorphism. 2020;4:45–52.
- World Health Organization. Draft landscape of COVID-19 candidate vaccines. 2020 Aug 13. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
- World Health Organization. Working Draft. Global Vaccine Market Report. 2019 Dec. https://www.who.int/immunization/programmes_systems/procurement/mi4a/platform/module2/2019_Global_Vaccine_Market_Report.pdf?ua=1.
- NIH News Release. Experimental HIV vaccine regimen ineffective in preventing HIV, Monday. 2020 Feb 3. https://www.nih.gov/news-events/news-releases/experimental-hiv-vaccine-regimen-ineffective-preventing-hiv (RV144 trial used heterologous prime-boost immunization strategy involving priming with original recombinant canarypox vector ALVAC vector (Sanofi) and booster injections of bivalent AIDSVAX gp120 immunogens (MN and A244 gp120, VaxGen) with rehydragel alum adjuvant. In contrast, HVTN-702 trial included a vaccination regimen of modified recombinant canarypox vector ALVAC vector with HIV subtype C env, subtype B gag, and pol inserts (Sanofi) and modified HIV‐1 subtype C Envelope bivalent gp120 subunit antigens (TV.1 and A244 gp120, Novartis/GSK) immunogens with MF59 adjuvant).
- Silbersher Z Does Moderna Therapeutics need to invalidate Arbutus Biopharma’s LNP patents? 2019 Oct 29. https://www.markmanadvisors.com/blog/2019/10/29/does-moderna-therapeutics-need-to-invalidate-arbutus-biopharmas-lnp-patents.
- H T T T, Pilkington E, Nguyen D, Seok Lee J, K D P, Truong N. The Importance of Poly(ethylene glycol) alternatives for overcoming PEG Immunogenicity in drug delivery and Bioconjugation. Polymers. 2020;12:298.
- Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020;182(4):1–16. doi:10.1016/j.cell.2020.06.043.